Accuray (ARAY) vs Elutia (ELUT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Elutia (ELUT) has outperformed Accuray (ARAY) over the past year, losing 6.9% versus a loss of 85.6%. Over five years, ELUT leads with a -84.8% price change compared with -93.9% for ARAY. Elutia is the larger company by market cap ($35.0 million vs $27.7 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARAY | ELUT |
|---|---|---|
| Share price | $0.2322 | $0.7905 |
| Market cap | $27.73M | $35.01M |
| 1-day change | -3.81% | -4.45% |
| YTD return | -70.56% | +19.38% |
| 1-year return | -85.63% | -6.94% |
| 5-year return | -93.86% | -84.82% |
| EPS (TTM) | $-0.40 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.10 | $1.39 |
| 52-week low | $0.22 | $0.50 |
| Distance from 52-week high | -88.94% | -42.92% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | — | +532.51% |
| Average volume | 7.22M | 185.82K |
| Shares outstanding | 119.44M | 44.29M |
| Employees | 809 | 25 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELUT has outperformed ARAY by 78.7 percentage points over the past year.
About Accuray
ARAY stock →Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Health Care · Medical/Dental Instruments · 809 employees
About Elutia
ELUT stock →Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 25 employees
ARAY vs ELUT FAQ
Which is bigger, Accuray or Elutia?
Elutia (ELUT) is larger, with a market capitalization of $35.01M compared with $27.73M for Accuray (ARAY).
Which stock has performed better over the past year, ARAY or ELUT?
ELUT returned -6.94% over the past 12 months, compared with -85.63% for ARAY (price return, excluding dividends). Past performance does not predict future results.
Are Accuray and Elutia in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Accuray and Biotechnology: Biological Products (No Diagnostic Substances) for Elutia.